632 related articles for article (PubMed ID: 7742583)
1. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
2. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
[TBL] [Abstract][Full Text] [Related]
3. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
[TBL] [Abstract][Full Text] [Related]
4. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
5. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
6. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
[TBL] [Abstract][Full Text] [Related]
7. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
8. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
10. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
[TBL] [Abstract][Full Text] [Related]
11. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
[TBL] [Abstract][Full Text] [Related]
13. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
14. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
Srivastava T; Zwick DL; Rothberg PG; Warady BA
Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
[TBL] [Abstract][Full Text] [Related]
15. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
16. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
[TBL] [Abstract][Full Text] [Related]
18. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
[TBL] [Abstract][Full Text] [Related]
19. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
Barkholt L; Linde A; Falk KI
Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
Benden C; Aurora P; Burch M; Cubitt D; Lloyd C; Whitmore P; Neligan SL; Elliott MJ
J Heart Lung Transplant; 2005 Dec; 24(12):2103-8. PubMed ID: 16364857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]